At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 251 enrolled
Drug / intervention
AGN-241751 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of AGN-241751 in Adult Participants With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating AGN-241751 and Placebo for Depressive Disorder, Major. Completed, enrolled 251 participants across 25 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJul 2018
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedJul 13, 2018
Enrollment StartJun 13, 2018
Primary CompletionJul 22, 2019
Study CompletionAug 21, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.0 years ago
Interventions
AGN-241751drug
AGN-241751 administered orally as a single tablet
Placebodrug
Placebo administered orally as a single tablet